Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNYSE:ABT
Date1/1990
Raised
Post IPO Valuation

General Information

Offices

Des Plaines, USA
1300 East Touhy
Des Plaines, IL, 60018-3315
USA

People

CEO
manager
Division Director
Multiple Positions
Staff Chemist
Chairman and Chief Executive Officer
Executive Vice President, Finance and Chief Financial Officer

Acquisitions

Total$8.79B
OptiMedica, 7/2013 $400M
IDEV Technologies, 7/2013 $310M
Facet Biotech, 3/2010 $450M
Solvay Pharmaceuticals, 9/2009 $6.6B
Evalve, 9/2009 $410M
Visiogen, 9/2009 $400M
Ibis Biosciences, 12/2008 $215M

Investments

Evalve 11/2007
Ovalis 1/2007

Funding

DEBT TOTAL $6.79M
Debt, 3/2009
$6.69M
Debt, 3/2011
$100k

Tags

Abbott Labs

Abbott Molecular Inc., a genomic disease management company, engages in the development and marketing of clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders, and other genetic diseases. It currently markets seven U.S. Food and Drug Administration or foreign cleared or approved clinical products in addition to distributing over 300 Analyte Specific Reagent and research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. The company was founded in 1991 and is based in Des Plaines, Illinois. As on 12/05/2001, Abbott Molecular Inc. operates as a subsidiary of Abbott Laboratories Inc.

Recent Milestones

Videos

Screenshots

Abbott Labs screenshot
Above: Home Page
Uploaded: 3/10/10

Stock Price

Traffic Analytics

Quantcast

Livegraph

Compete

Abbott

Sources

  1. Abbott to pay up to $400M to buy OptiMedica (bizjournals.com) [edit]
  2. Abbott to Acquire IDEV Technologies to Expand Global Peripheral Technology Portfolio (abbott.com) [edit]
  3. Abbott buys Facet Biotech for $450M (fiercebiotech.com) [edit]
  4. Abbott to buy Solvay pharma unit in $6.6B deal (fiercebiotech.com) [edit]
  5. Studies find Botox cuts migraine days; Abbott to buy Evalve for up to $410M (fiercepharma.com) [edit]
  6. Abbott To Pay $400 Million For Cataract-Treatment Firm Visiogen (smartmoney.com) [edit]
  7. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis (reuters.com) [edit]
  8. Evalve pulls in $60M, heating up heart-valve implant race (venturebeat.com) [edit]
  9. Ovalis, Inc.: Series B $6.6M (onbiovc.com) [edit]
  10. SEC (sec.gov) [edit]
  11. SEC (sec.gov) [edit]
  12. Abbott Buys Action Pharma Hormone For $110M (pevc.dowjones.com) [edit]
    Abbott closes $250M deal for eye surgery biz (fiercemedicaldevices.com) [edit]
Edit This Page
Last Edited 4/15/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy